The Tau N279K Exon 10 Splicing Mutation Recapitulates Frontotemporal Dementia and Parkinsonism Linked to Chromosome 17 Tauopathy in a Mouse Model
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Intracellular tau deposits are characteristic of several neurodegenerative disorders called tauopathies. The tau protein regulates the stability and assembly of microtubules by binding to microtubules through three or four microtubule-binding repeats (3R and 4R). The number of microtubule-binding repeats is determined by the inclusion or exclusion of the second microtubule-binding repeat encoded by exon 10 of the TAU gene.TAU gene mutations that alter the inclusion of exon 10, and hence the 4R:3R ratio, are causal in the tauopathy frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). A mutation located in exon 10 has been identified in several FTDP-17 families that present with increased exon 10 inclusion in both mRNA and protein, parkinsonism, movement disorders, and dementia. We have engineered a human tau minigene construct that was designed to allow alternative splicing of the tau exon 10. Here we demonstrate that transgenic mice expressing human tau protein with this mutation develop neurodegeneration as result of aberrant splicing. The mice recapitulate many of the disease hallmarks that are seen in patients with this mutation, including increased tau exon 10 inclusion in both mRNA and protein, motor and behavioral deficits, and tau protein accumulation in neurons and tufted astrocytes. Furthermore, these mice present with degeneration of the nigrostriatal dopaminergic pathway, suggesting a possible mechanism for parkinsonism in FTDP-17. Additionally, activated caspase-3 immunoreactivity in both neurons and astrocytes implicates the involvement of the apoptotic pathway in the pathology of these mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
A protein factor essential for microtubule assembly
Weingarten, M. D., Lockwood, A. H., Hwo, S. Y., & Kirschner, M. W. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.5.1858 · Cited by 3,089
West, M. J., Slomianka, L., & Gundersen, H. J. G. (1991) · The Anatomical Record · doi:10.1002/ar.1092310411 · Cited by 2,994
Mutation in the tau gene in familial multiple system tauopathy with presenile dementia
Spillantini, M. G., Murrell, J. R., Goedert, M., Farlow, M. R., Klug, A., & Ghetti, B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7737 · Cited by 1,474 · cited 2×
“The identification of TAU gene mutations in families with FTDP-17 tauopathy has provided firm evidence that abnormal tau expression is sufficient to cause neurodegeneration (Foster et al., 1997; Hutton et al., 1998; Poorkaj et al., 1998; Spillantini et al., 1998; Reed et al., 2001; Rademakers et al., 2004).”
BackgroundTau is a candidate gene for chromosome 17 frontotemporal dementia
Poorkaj, P., Bird, T. D., Wijsman, E., Nemens, E., Garruto, R. M., Anderson, L., Andreadis, A., Wiederholt, W. C., Raskind, M., & Schellenberg, G. D. (1998) · Annals of Neurology · doi:10.1002/ana.410430617 · Cited by 1,374 · cited 1×
“…of TAU gene mutations in families with FTDP-17 tauopathy has provided firm evidence that abnormal tau expression is sufficient to cause neurodegeneration (Foster et al., 1997; Hutton et al., 1998; Poorkaj et al., 1998; Spillantini et al., 1998; Reed et al., 2001; Rademakers et al., 2004).”
BackgroundFluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration
Schmued, L. C., & Hopkins, K. J. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02513-0 · Cited by 1,218 · cited 2×
“Fluoro-Jade B is a polyanionic fluorescein derivative that binds to degenerating neurons (Schmued and Hopkins, 2000).”
BackgroundResultGoedert, M., Spillantini, M. G., Potier, M. C., Ulrich, J., & Crowther, R. A. (1989) · The EMBO Journal · doi:10.1002/j.1460-2075.1989.tb03390.x · Cited by 1,037
Goedert, M., & Jakes, R. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb07870.x · Cited by 929 · cited 1×
“The 4R tau isoforms contain additional amino acids encoded by exon 10 that are absent in the 3R isoforms (Goedert and Jakes, 1990; Shahani and Brandt, 2002).”
BackgroundCaspase cleavage of tau: Linking amyloid and neurofibrillary tangles in Alzheimer's disease
Gamblin, T. C., Chen, F., Zambrano, A., Abraha, A., Lagalwar, S., Guillozet, A. L., Lu, M., Fu, Y., Garcia-Sierra, F., LaPointe, N., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1630428100 · Cited by 831
Ebneth, A., Godemann, R., Stamer, K., Illenberger, S., Trinczek, B., Mandelkow, E.-M., & Mandelkow, E. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.143.3.777 · Cited by 820
Advanced glycation end products contribute to amyloidosis in Alzheimer disease
Vitek, M. P., Bhattacharya, K., Glendening, J. M., Stopa, E., Vlassara, H., Bucala, R., Manogue, K., & Cerami, A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.11.4766 · Cited by 806 · cited 1×
“This nucleation seeding hypothesis is well known to function in tauopathy, prion disease, and amyloid aggregates (Vitek et al., 1994; King et al., 1999; Gamblin et al., 2000, 2003b).”
BackgroundSelf-citationAssociation of an Extended Haplotype in the Tau Gene with Progressive Supranuclear Palsy
Baker, M., Litvan, I., Houlden, H., Adamson, J., Dickson, D., Perez-Tur, J., Hardy, J., Lynch, T., Bigio, E., & Hutton, M. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.4.711 · Cited by 781 · cited 1×
“…the H1 haplotype is associated with several polymorphisms and occurs with increased frequency in patients with PSP and CBD (Oliva et al., 1998; Baker et al., 1999; Ezquerra et al., 1999; Di et al., 2000; de Silva et al., 2001; Houlden et al., 2001; Liu et al., 2001; Pastor et al., 2002;…”
BackgroundNeurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs
Forman, M. S., Trojanowski, J. Q., & Lee, V. M.-Y. (2004) · Nature Medicine · doi:10.1038/nm1113 · Cited by 715 · cited 2×
“Tauopathies are clinically distinguished by dementia and behavioral and motor dysfunction and include frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), Alzheimer’s disease (AD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and Pick’s disease (Goedert and Hasegawa, 19…”
BackgroundDomains of tau Protein and Interactions with Microtubules
Gustke, N., Trinczek, B., Biernat, J., Mandelkow, E.-M., & Mandelkow, E. (1994) · Biochemistry · doi:10.1021/bi00198a017 · Cited by 655 · cited 1×
“Because 4R tau binds to microtubules threefold more tightly than 3R tau (Butner and Kirschner, 1991; Gustke et al., 1994; Goode et al., 2000; Panda et al., 2003; Levy et al., 2005), we theorize that this stronger microtubule– 4R interaction disrupts the equilibrium of microtubule-bound tau and…”
BackgroundTau protein binds to microtubules through a flexible array of distributed weak sites.
Butner, K. A., & Kirschner, M. W. (1991) · The Journal of cell biology · doi:10.1083/jcb.115.3.717 · Cited by 550
Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology
Rissman, R. A., Poon, W. W., Blurton-Jones, M., Oddo, S., Torp, R., Vitek, M. P., LaFerla, F. M., Rohn, T. T., & Cotman, C. W. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420640 · Cited by 543 · cited 2×
“…in apoptotic cell death, has been implicated in the neuronal loss observed in tauopathies, including Alzheimer’s disease (AD), and has been shown to cleave tau protein (Fasulo et al., 2000; Berry et al., 2003; Gamblin et al., 2003a; Rissman et al., 2004; Cotman et al., 2005; Newman et al., 2005).”
BackgroundSelf-citationInhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice
Dawson, H. N., Ferreira, A., Eyster, M. V., Ghoshal, N., Binder, L. I., & Vitek, M. P. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.6.1179 · Cited by 527
Self-citationCorticobasal degeneration and progressive supranuclear palsy share a common tau haplotype
Houlden, H., Baker, M., Morris, H. R., MacDonald, N., Pickering–Brown, S., Adamson, J., Lees, A. J., Rossor, M. N., Quinn, N. P., Kertesz, A., et al. (2001) · Neurology · doi:10.1212/wnl.56.12.1702 · Cited by 409 · cited 5×
“Specifically, this group of diseases may include PSP, CBD, argyrophilic grain disease, and other FTDP-17 diseases resulting from exon 10 splicing mutations (Mailliot et al., 1998; Sergeant et al., 1999; Arai et al., 2001; Liu et al., 2001; Togo et al., 2002; Katsuse et al., 2003; Morris et al., 2003).”
BackgroundInfluentialPanda, D., Samuel, J. C., Massie, M., Feinstein, S. C., & Wilson, L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1633508100 · Cited by 280
Argyrophilic Grain Disease Is a Sporadic 4-Repeat Tauopathy
Togo, T., Sahara, N., Yen, S.-H., Cookson, N., Ishizawa, T., Hutton, M., de Silva, R., Lees, A., & Dickson, D. W. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.6.547 · Cited by 273
Klein, R. L., Dayton, R. D., Leidenheimer, N. J., Jansen, K., Golde, T. E., & Zweig, R. M. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.10.008 · Cited by 200
The Role of Caspase Cleavage of Tau in Alzheimer Disease Neuropathology
Cotman, C. W., Poon, W. W., Rissman, R. A., & Blurton-Jones, M. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/64.2.104 · Cited by 199
Transgenic Mouse Model of Tau Pathology in Astrocytes Leading to Nervous System Degeneration
Forman, M. S., Lal, D., Zhang, B., Dabir, D. V., Swanson, E., Lee, V. M.-Y., & Trojanowski, J. Q. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.0081-05.2005 · Cited by 198 · cited 2×
“Furthermore, a recent report by Forman et al. (2005) showed that transgenic mice that overexpress tau protein in astrocytes alone develop astrocytic pathology in the form of tufted astrocytes and are associated with focal neuronal injury.”
BackgroundInhibition of Tau Polymerization by Its Carboxy-Terminal Caspase Cleavage Fragment
Berry, R. W., Abraha, A., Lagalwar, S., LaPointe, N., Gamblin, T. C., Cryns, V. L., & Binder, L. I. (2003) · Biochemistry · doi:10.1021/bi027348m · Cited by 141
Yoshiyama, Y., Zhang, B., Bruce, J., Trojanowski, J. Q., & Lee, V. M.-Y. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-33-10662.2003 · Cited by 72 · cited 1×
“Previous experiments have shown that the overexpression of tau protein in primary rat astrocytes caused a clustering of kinesin, a microtubule transport molecule (Yoshiyama et al., 2003).”
BackgroundEzquerra, M., Pastor, P., Valldeoriola, F., Luis Molinuevo, J., Blesa, R., Tolosa, E., & Oliva, R. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00738-7 · Cited by 58 · cited 5×
“Specifically, this group of diseases may include PSP, CBD, argyrophilic grain disease, and other FTDP-17 diseases resulting from exon 10 splicing mutations (Mailliot et al., 1998; Sergeant et al., 1999; Arai et al., 2001; Liu et al., 2001; Togo et al., 2002; Katsuse et al., 2003; Morris et al., 2003).”
BackgroundInfluentialTangled areas of Alzheimer brain have upregulated levels of exon 10 containing tau mRNA
Yasojima, K., McGeer, E. G., & McGeer, P. L. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01486-9 · Cited by 51 · cited 1×
“The levels of 4R tau mRNA (Yasojima et al., 1999) and 3R tau mRNA (no exon 10) were quantified using RT-PCR.”
Method
Cited by
Alternative splicing and disease
Tazi, J., Bakkour, N., & Stamm, S. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.09.017 · Cited by 540
Glial contributions to neurodegeneration in tauopathies
Leyns, C. E. G., & Holtzman, D. M. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0192-x · Cited by 409
Increased 4R-Tau Induces Pathological Changes in a Human-Tau Mouse Model
Schoch, K. M., DeVos, S. L., Miller, R. L., Chun, S. J., Norrbom, M., Wozniak, D. F., Dawson, H. N., Bennett, C. F., Rigo, F., & Miller, T. M. (2016) · Neuron · doi:10.1016/j.neuron.2016.04.042 · Cited by 175
Self-citationHuman iPSC application in Alzheimer’s disease and tau-related neurodegenerative diseases
TCW, J. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.01.043 · Cited by 39
Metadata
- Authors
- Dawson, H. N., Cantillana, V., Chen, L., & Vitek, M. P.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2007-08-22
- Volume
- 27
- Issue
- 34
- Pages
- 9155-9168
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W2086021621
- Cited by
- 79
- References
- 27
- FWCI
- 3.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.